Biocept Ceo

In this SNNLive Video Interview, our host spoke with Mike Nall, CEO of Biocept, Inc. SAN DIEGO, June 5, 2020 /PRNewswire/ — Biocept, Inc. BIOC 18/06/2020 18:02:23 1-888-992-3836 Free. Table 2 shows the detailed insider transactions. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. SAN DIEGO, June 5, 2020 /PRNewswire/ -- Biocept, Inc. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's. Biocept, Inc. 4 Biocept reviews. If you believe we have made an error, call the newsroom at 863-385-6155. Prior to joining Clarient, Mr. Biocept (NASDAQ: BIOC) this morning said it has been awarded a Japanese patent covering the use of antibodies for the capture of any target of interest from any sample type on a device surface including circulating tumor cells (CTCs). Maxim Group began coverage on shares of Biocept (NASDAQ:BIOC) in a report issued on Friday morning, TipRanks reports. | 1,437 followers on LinkedIn | Cynvenio Biosystems, Inc. Biocept CEO and key executive team. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information. Für Biocept liegen aus den letzten zwölf Monaten 1 Buy, 0 Hold und 0 Sell Einschätzungen von Analysten vor, was im Schnitt einem „Buy“-Rating entspricht. Jody Cain - LHA, IR. , a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces that it is relocating its corporate offices and CLIA-certified, CAP-accredited high complexity laboratory to a new location in San Diego. Michael Nall, Biocept’s President and CEO, remarked: The promise of liquid biopsy is beginning to be realized broadly, given the ability to use a simple blood sample to access the same information found with an invasive tissue biopsy. Real-time discussion about Biocept, Inc. (BIOC) CEO Michael Nall on Q4 2019 Results - Earnings Call Transcript 8:15PM ET 3/25/2020 Seeking Alpha Biocept (BIOC) Presents At BIO CEO & Investor Conference 2020 - Slideshow. Hale was appointed Executive Chairman of Biocept in March 2011. About Biocept Biocept, Inc. Nall: This is to advise you that we have not reviewed and will not review your registration. Biocept President and CEO,. Biocept, Inc. Report this profile; Activity. Nall will present a corporate overview at the 22 nd Annual BIO CEO & Investor Conference on Monday. 4 million, representing a 41% increase over the prior-year period driven by a 27% increase in revenue per commercial accession," said Michael Nall, President and CEO of Biocept. Article Stock Quotes (1) Biocept, Inc. 36 and it is a. Analysts predict that the stock will reach $4. Biocept Expands its Menu of Molecular Assay Kit Offering with Release of its Target Selector™ BRAF Kit for Clients' Use in Their Own Laboratories: May 14: 32 Stocks Moving in Thursday's Pre-Market Session: May 14: Biocept, Inc. Biocept, Inc. Biocept President and CEO, will participate on the panel "COVID-19 Testing & Susceptibility. ThermoFisher is one of. Investors: Privately funded by the Reiss family and other undisclosed investors. Evoshield is committed to achieving Level AA conformance with the Web Content Accessibility Guidelines (WCAG) 2. (NASDAQ: BIOC) The 36 Months beta value for BIOC stocks is at 1. (BIOC) on CEO. The agreement with BCBS IL is also the company's first within the larger Blue Cross Blue Shield system. 1: Biocept Inc. Reiss, Chairman of the Board. via Skype, and they discuss the following topics:. 09, FLORIDA STATUTES NOTICE IS HEREBY GIVEN that the undersigned, desiring to engage in business under the fictitious name of NO LIMIT RV SERVICES located at P. The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. SAN DIEGO, May 20, 2020 /PRNewswire/ -- Biocept, Inc. | 1,437 followers on LinkedIn | Cynvenio Biosystems, Inc. Nall will present a corporate overview at the 22 nd Annual BIO CEO & Investor Conference on Monday. 54,564 Watchers. "I am very thankful to our laboratory team for stepping up and quickly validating COVID-19 testing, in addition to the vital work we do each day for patients diagnosed with cancer," Biocept CEO. For more information on Biocept's Target Selector™ liquid biopsy kits, or to order Assay Kits, please contact Biocept Customer Service at (888) 332-7729 or go to [email protected] Foletta (“ Executive ”), and shall be effective as of August 18, 2015 (the “ Effective Date ”). 's ISS Governance QualityScore as of N/A is N/A. via Skype, and they discuss. highlandsnewssun. The stock has a beta of 0. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces the availability of 10,000 nasopharyngeal specimen collection kits for RT-PCR testing for SAR-CoV-2 (COVID-19) for physician ordering. See Michael W Nall's compensation, career history, education, & memberships. Biocept Inc. SAN DIEGO, Feb. Biocept says it plans to launch its first product, a diagnostic test for breast cancer, later this year. However, it had a very good returns during the last 30 days. 4 Biocept reviews. Thursday, October 01, 2015 $BIOC Biocept CEO Discusses Liquid Biopsy Diagnostic Test - StockNewsNow. 09, FLORIDA STATUTES NOTICE IS HEREBY GIVEN that the undersigned, desiring to engage in business under the fictitious name of NO LIMIT RV SERVICES located at P. At the time of writing, our data says that Biocept, Inc. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's. SAN DIEGO, April 28, 2020 /PRNewswire/ -- Biocept, Inc. 61 %, while year-to-date (YTD) performance is 52. Find 4 questions and answers about working at BIOCEPT. (NASDAQ:BIOC) Q2 2019 Earnings Conference Call August 12, 2019 4:30 PM ET Company Participants. 7, 2019 /PRNewswire/ -- Biocept, Inc. 4 million, representing a 41% increase over the prior-year period driven by a 27% increase in revenue per commercial accession," said Michael Nall, President and CEO of Biocept. Biocept (BIOC) Presents At BIO CEO & Investor Conference 2020 - Slideshow. SAN DIEGO, Feb. Biocept, Inc. BioCryst shares were gaining 21. What's more, Nall says, is the California-based company is expanding its coronavirus molecular diagnostic test to its current client base, with a current capacity of 100 tests per day, with the. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample. 13, 2020 at 8:41 p. Industry, sector and description for Biocept. Nall has over 30 years of leadership experience in healthcare sales,. Hale is a Chairman at Adigica Health, Inc. May 20, 2020, 08:05 ET. People are so nice, and they really are like a family. What's more, Nall says the developer of liquid biopsy tests has released a new Target Selector molecular assay research-use-only kit for clients to use in their own laboratories. Analysts Date Brokerage Action Rating. Biocept, Inc. We have curated daily news headlines, active forums where users can post anonymously, job listings and more. Biocept's revenue is the ranked 6th among it's top 10 competitors. 7729 Company Operator: 858. We partner with industry leaders and major cancer centers, continually advancing the field of. Michael Nall - President & CEO. SAN DIEGO, April 28, 2020 /PRNewswire via COMTEX/ -- SAN DIEGO, President and CEO of Biocept. “Our agreement with OHSU is a major milestone for Biocept, as we increase our commercial footprint by partnering with one of the most prestigious cancer centers in the nation,” said Michael W. Biocept to begin coronavirus testing Local. November 13, 2019, 04:30 PM ET. (NASDAQ:BIOC) in 2013. 42 and spell out a more modest performance – a 89. Namaste Technologies Inc (CVE:N) (OTCMKTS:NXTTF) announced Monday its subsidiary CannMart Inc has been granted an exclusive license by IGNITE International Brands Ltd (CSE:BILZ) (OTCQX: BILZF) to utilize certain brand trademarks on cannabis-based products for sale in Canada. 11, 2020 12:11 PM ET The following slide deck was published by Biocept, Inc. The company has a one-year high of $22. SAN DIEGO, June 5, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ:BIOC), a leading commercial. The development of this important technology is a prime example of how Biocept intends to leverage its proprietary technologies and intellectual property to improve the standard of care for cancer patients and to increase the value of our company for shareholders,” Biocept president and CEO Michael Nall stated in the news release. Michael Nall, president and CEO of Biocept, said in a statement that gaining coverage by individual health plans like BCBS IL is a key aspect of the company's reimbursement strategy. Real-time discussion about Biocept, Inc. 44 percent to $1. Wilson is also a member of the board of directors of BioMed Realty Trust, Inc. Michael Nall, President and CEO of Biocept, commented, "We believe the findings from this study are valuable as they help in our understanding of ovarian cancer metastasis, and how to improve. The company trades on NASDAQ, ticker symbol BIOC, currently trading at $1. BioCryst shares were gaining 21. He is the Chairman & CEO of Hale BioPharma Ventures LLC, a private company focused on the formation and development of biotechnology, specialty pharma, diagnostic and medical device companies. Analysts predict that the stock will reach $4. org, Humor Train,. Biocept, Inc. It was established in 1992, journalists, photographers, correspondents, researchers came to the publication from the editorial offices of regional newspapers, drama theater, etc. Biocept Inc (NASDAQ: BIOC) CEO Mike Nall tells Proactive the molecular diagnostics company, is expanding uses for its flagship liquid biopsy Target Selector technology which detects cancer biomarkers. is a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the. Benzinga is covering every angle of how the coronavirus affects the financial world. If you believe we have made an error, call the newsroom at 863-385-6155. (This number is for the twelve months until December 2018). (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces that it is relocating its corporate offices and CLIA-certified, CAP-accredited high complexity laboratory to a new location in San Diego. 62% soared 86% on very heavy volume Monday, after the provider of liquid biopsy tests announced the commercial launch of Target Selector NGS Lung Panel, the liquid biopsy panel developed for lung cancer. 4, 2020 /PRNewswire/ -- Biocept, Inc. August 2016—Biocept launched its CLIA-validated PD-L1 protein expression test, which uses Biocept’s proprietary, patented Target Selector platform with circulating tumor cells from a patient’s blood sample and can be used to detect and monitor PD-L1 protein expression throughout the course of a patient’s cancer therapy. is a leader in the development of more affordable and clinically actionable precision medicine strategies for the individual cancer patient. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. Please contact Customer Service at 1-800-401-7919, if you have any issues accessing information on this website. SAN DIEGO, Feb. Great Bear Resources (CVE: GBR-OTCQX: GTBAF) President and CEO Chris Taylor joined Steve Darling from Proactive Vancouver to share news the company has brought on a mining industry veteran to the board. [ May 27, 2020 ] Co-Diagnostics, Inc. Our liquid biopsies have been used by doctors in thousands of patient cases. (NASDAQ:BIOC) since 2013. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces the availability of 10,000 nasopharyngeal specimen collection kits for RT-PCR testing for SAR-CoV-2 (COVID-19) for physician ordering. Biocept, Inc. Biocept is trading at 0. 1: Biocept Inc. Among the significant. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. Biocept is a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor associated DNA , both in Circulating Tumor Cells (CTCs) and in plasma (cell free. Nall Ceo 88 Number of Employees. stocks as a “buy” while as. Biocept Inc. Biocept, Inc. Biocept, Inc. People are so nice, and they really are like a family. SAN DIEGO, June 5, 2020 /PRNewswire/ -- Biocept, Inc. Gratis precios de la bolsa en tiempo real, y los foros más activos del mercado accionario. Nall made $439,720 in total compensation. Michael Nall, Biocept’s President and CEO, added, “This is our third patent issued in Japan, strengthening the protection of our proprietary liquid biopsy technology in an important healthcare market. SAN DIEGO, June 24, 2020 /PRNewswire/ -- Biocept, Inc. 1: Biocept Inc. The agreement with BCBS IL is also the company's first within the larger Blue Cross Blue Shield system. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information. Michael Nall, president and CEO of Biocept, said in a statement that gaining coverage by individual health plans like BCBS IL is a key aspect of the company's reimbursement strategy. As an accomplished commercial and operational leader, Todd most recently served as CEO of LABS, a medical service laboratory, which was acquired by Eurofins. Coronavirus Testing Expands In San Diego County pleased to support our clients and public health efforts by expanding our offerings to include COVID-19 testing," said Biocept CEO Mike Nall. 09, FLORIDA STATUTES NOTICE IS HEREBY GIVEN that the undersigned, desiring to engage in business under the fictitious name of NO LIMIT RV SERVICES located at P. Biocept to Present at the 22nd Annual BIO CEO & Investor Conference. (BIOC) CEO Michael Nall on Q1 2020 Results - Earnings Call Transcript May. (NASDAQ: BIOC) via Skype. Focused on rapid advancement in the molecular biology field, Cynvenio’s genomic tests accurately target known mutations in cancer-related genes to revolutionize. The Company focuses on developing and commercialization proprietary circulating tumor cell and circulating tumor DNA tests. com reaches roughly 2,646 users per day and delivers about 79,389 users each month. Hale is a Chairman at Adigica Health, Inc. 91: 675,000 (Direct) View: 2019-04-30 Option Award: 2019-06-19 4:23 pm: N/A 2029-04-29: BIOCEPT INC: BIOC: HALE DAVID F Director: 30,000: $0. SAN DIEGO, Feb. Biocept Launches Liquid Biopsy Research Kits for Cancer Gene Mutations. , a real estate investment trust. Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the promotion of Cory J. Cafepharma is a site for the pharmaceutical/medical industry. May 20, 2020, 08:05 ET. SAN DIEGO, April 28, 2020 /PRNewswire/ -- Biocept, Inc. Real-time Insider Trading Stock Screener. 91: 500 (Direct) View: 2019-04-30 Option Award: 2019-06-19 4:23 pm: N/A 2029-06-16: BIOCEPT INC: BIOC: HALE DAVID F Director: 500: $1. Jubilee Metals CEO Leon Coetzer on Strategy, COVID 19, Strength and Opportunity (Interview). 2017 im w:o-Forum 'Biotech'. The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. Biocept CEO Michael Nall Now the company has its eye on expansion, planning to roll out similar tests for colorectal cancer and melanomas in the year to come, CEO Michael Nall told FierceDiagnostics. Benzinga is covering every angle of how the coronavirus affects the financial world. Nall, Biocept President and CEO, will participate on the panel "COVID-19 Testing & Susceptibility - Clearing the. "Revenue for the first quarter was $1. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. SAN DIEGO, June 22, 2020 /PRNewswire/ -- Biocept, Inc. Biocept announced yesterday that Michael Nail, President and CEO of the company, will be giving a presentation at the LD Micro Invitational Conference on June 1, at 1:00PM Pacific time. Biocept and Clarient have entered a collaboration to commercialize a blood test for circulating tumor cells (CTCs) in breast cancer patients, which includes the determination of Her2 status. 站点统计:224个分类 12044个标签 5987 篇文章 1952条留言 浏览量:12027665 最后更新:2020年6月22日. (NASDAQ: BIOC) via Skype. Biocept (BIOC) Presents At BIO CEO & Investor Conference 2020 - Slideshow. (BIOC) CEO Michael Nall on Q1 2020 Results – Earnings Call Transcript Seeking Alpha Stocks 25 mins S&P 500: An island reversal on daily chart points to further downside – Forbes FXStreet. Gratis precios de la bolsa en tiempo real, y los foros más activos del mercado accionario. (NASDAQ:BIOC) Q1 2020 Results Conference Call May 13, 2020 4:30 PM ET Company Participants. 5810 Nancy Ridge Dr. stock is -63. A free inside look at company reviews and salaries posted anonymously by employees. Berkshire (aktiencheck. Biocept also announced the resignation of its former CEO, President and Director, Gordon F. Biocept, Inc. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Biocept against related stocks people have also bought. Ivor Royston M. I have been working at Biocept full-time (More than a year) Pros. The average Chief Executive Officer salary in the United States is $815,636 as of May 28, 2020, but the range typically falls between $628,910 and $1,014,059. Biocept's President and CEO. Biocept is a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor associated DNA , both in Circulating Tumor Cells (CTCs) and in plasma (cell free circulating tumor DNA). ) "MCCP has a reputation for paying out-of-network claims correctly, in full and on time; and we are delighted to be working with them," said Dede Goehler, Biocept's Senior Director of Managed Care Strategies. 02: 500 (Direct. Cotización Biocept (BIOC), gráficas, operaciones, ranking de las acciones, índices, blogs y foros más populares de la BMV y mucho más. Biocept to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020. “The letter to the editor represents another important case study in which our Target Selector™ liquid biopsy platform has demonstrated the ability to inform physicians on the molecular information driving a patient’s cancer, so that optimum therapy can be selected for treatment,” said Biocept’s President and CEO Michael Nall. It is worth noting that the CEO compensation consists almost entirely of the salary, worth US$426k. has a market cap of US$18m, and reported total annual CEO compensation of US$440k for the year to December 2018. Conference Call Participants. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to. Panel Session Title: Testing & Susceptibility - Clearing the Air Date and Time: Wednesday, May 27, 12:00 p. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that Michael W. What's more, Nall says, is the California-based company is expanding its coronavirus molecular diagnostic test to its current client base, with a current capacity of 100 tests per day, with the. Biocept, Inc. Trova la discussione più recente sui titoli Guardant Health, Inc. Biocept's President and CEO. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that Michael W. Nall, Biocept President and CEO, will participate on the panel "COVID-19 Testing & Susceptibility - Clearing the Air. (BIOC) is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. Table 1 shows the monthly insider trading data at Biocept Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO. Hale, 70 Non-Executive Chairman, Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The agreement with BCBS IL is also the company's first within the larger Blue Cross Blue Shield system. The Board of Directors of Biocept Inc. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces that it is relocating its corporate offices and CLIA-certified, CAP-accredited high complexity laboratory to a new location in San Diego. 4, 2020 /PRNewswire/ -- Biocept, Inc. , a real estate investment trust. Nall: This is to advise you that we have not reviewed and will not review your registration. | Biocept is a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor associated DNA , both in Circulating Tumor Cells (CTCs) and in plasma (cell free circulating tumor DNA). 2 Wall Street analysts have issued ratings and price targets for Biocept in the last 12 months. Tim Kennedy - SVP, Operations & CFO. Biocept is trading at 0. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that Michael W. Biocept Announces CE-IVD Mark And Availability Of Its Target Selector™ EGFR Molecular Assay Kit In Europe. Address: 5810 Nancy Ridge Drive, Suite 150, San Diego, CA, USA, 92121: Telephone: +1 858 320-8200: Website: https://www. Michael Nall President and CEO at Biocept Orange County, California Area 500+ connections. Linda Macander Executive Assistant to CEO at Biocept Greater San Diego Area Biotechnology. DA: 18 PA: 50 MOZ Rank: 50. 5M in cash: 9. Nall, Biocept President and CEO, will participate on the panel "COVID-19 Testing. The Company focuses on developing and commercialization proprietary circulating tumor cell and circulating tumor DNA tests. Cotización Biocept (BIOC), gráficas, operaciones, ranking de las acciones, índices, blogs y foros más populares de la BMV y mucho más. The patent, entitled “Devices And Methods Of Cell Capture And Analysis,” is broader than previously issued … Continue reading "NetworkNewsBreaks. (CGI) is committed to enhancing the development of advanced therapies in precision medicine. (NASDAQ:BIOC) since 2013. (BIOC) CEO Michael Nall on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha]-11. employment agreement This Employment Agreement (this “ Agreement ”) is entered into by and between Biocept, Inc. Foletta (“ Executive ”), and shall be effective as of August 18, 2015 (the “ Effective Date ”). August 2016—Biocept launched its CLIA-validated PD-L1 protein expression test, which uses Biocept’s proprietary, patented Target Selector platform with circulating tumor cells from a patient’s blood sample and can be used to detect and monitor PD-L1 protein expression throughout the course of a patient’s cancer therapy. Biocept Inc (NASDAQ:BIOC) a major commercial provider of liquid biopsy assessments intended to offer physicians with clinically actionable data to enhance the outcomes of cancer patients, reported that CEO and President W. Biocept President and CEO, will participate on the panel "COVID-19 Testing & Susceptibility. ET on Seeking Alpha Biocept up 12% premarket on assay nod in Europe. 27% to trade at $2. Biocept also announced the resignation of its former CEO, President and Director, Gordon F. SAN DIEGO, May 13, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to provide information to. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that Michael W. The Company uses its proprietary liquid biopsy technology to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with cancer. (NASDAQ:BIOC) Q2 2019 Earnings Conference Call August 12, 2019 4:30 PM ET Company Participants. Over 70% of our closed positions are for gains of 50% or greater. Michael Nall, Biocept’s President and CEO, added, “This is our third patent issued in Japan, strengthening the protection of our proprietary liquid biopsy technology in an important healthcare market. 4, 2020 /PRNewswire/ -- Biocept, Inc. Tim Kennedy - SVP. About Biocept. , LLC, a business management and strategic planning consulting firm, since 2003. Biocept, Inc. (BIOC) is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. 11, 2020 12:11 PM ET The following slide deck was published by Biocept, Inc. com uses a Commercial suffix and it's server(s) are located in N/A with the IP number 104. If you believe we have made an error, call the newsroom at 863-385-6155. is Independent Director of the Company. Biocept has a market cap of $38. has a market cap of US$19m, and is paying total annual CEO compensation of US$440k. Cafepharma is a site for the pharmaceutical/medical industry. Biocept, Inc. The goals are to improve health outcomes by using liquid biopsy to more rapidly assess a patient’s molecular status and select an appropriate therapy, while. People are so nice, and they really are like a family. Revenues increased sharply and topped the Street view, while the bottom-line missed. , a Delaware corporation (the “ Company ”), and Mark G. 2017 im w:o-Forum 'Biotech'. 27% to trade at $2. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. A group of progressive California lawmakers and district attorneys announce they will reject donations from police unions. BIOC Stock Pops After Being Awarded A New Patent. Cynvenio Biosystems, Inc. Monitor SEC Form 4 Insider Trading Filings for Insider Buying and Selling. For expert network information on Biocept, Inc. Table 2 shows the detailed insider transactions. About Biocept. They set a buy rating for […]. Nall will present a corporate overview at the 22 nd Annual BIO CEO & Investor Conference on Monday, February 10,. 23, 2018 /PRNewswire/ -- Biocept, Inc. Nall, Biocept President and CEO, will participate on the panel "COVID-19 Testing. BIOC Stock Pops On CFS Testing Availability. Here's the scoop: Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!. Biocept, a molecular diagnostics company focused on liquid biopsies for cancer, recently announced an expansion of its product portfolio with the launch of a blood test for PD-L1 protein expression - a crucial tool for determining immuno-oncology treatment. 4 Biocept reviews. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. In addition, CannMart has received approval from Alberta Gaming, Liquor & Cannabis (AGLC). Biocept To Accept COVID-19 Testing Requests. The only penny stocks site recommended in Barron's and by Forbes, picks penny stocks trading at under $5 a share that are on the NYSE, NASDAQ, and AMEX. Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. Industry, sector and description for Biocept. Biocept has a very high chance of experiencing financial distress in the next few years of operation. (NASDAQ:BIOC) in 2013. See Michael W Nall's compensation, career history, education, & memberships. Biocept, Inc. Biocept announced yesterday that Michael Nail, President and CEO of the company, will be giving a presentation at the LD Micro Invitational Conference on June 1, at 1:00PM Pacific time. Business: Diagnostic Hired: Michael Nall as president and CEO, formerly general manager of North American sales and marketing at General Electric's Clarient Diagnostic Services Inc. SI) including stock quotes, financial news, historical charts, company background, company fundamentals, company financials, insider trades, annual reports and historical prices in the Company Factsheet. BIOCEPT INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents. Its 52-week range is between 0. Hale and 8 others. 4 million, representing a 41% increase over the prior-year period driven by a 27% increase in revenue per commercial accession," said Michael Nall, President and CEO of Biocept. Michael Nall - President & CEO. SAN DIEGO, Feb. Biocept Inc. 6 million each quarter. NASDAQ Updated Jun 24, 2020 8:04 PM. Nall, Biocept President and CEO, will participate on the panel "COVID-19 Testing & Susceptibility - Clearing the Air". (Image via iStock) The post Daily Business Report-June 8, 2020. View the real-time BIOC price chart on Robinhood and decide if you want to buy or sell commission-free. (NASDAQ:BIOC) in 2013. This is the Biocept company profile. What's more, Nall says the developer of liquid biopsy tests has released a new Target. Among the significant. Biocept (BIOC) Presents At BIO CEO & Investor Conference 2020 - Slideshow. Nall has over 30 years of leadership experience in healthcare sales,. Biocept Inc (NASDAQ:BIOC) a major commercial provider of liquid biopsy assessments intended to offer physicians with clinically actionable data to enhance the outcomes of cancer patients, reported that CEO and President W. Nall Chief Executive Officer and President Biocept, Inc. Nall, Biocept's President and CEO. 8M; in Q3 2019, it was $1. “The letter to the editor represents another important case study in which our Target Selector™ liquid biopsy platform has demonstrated the ability to inform physicians on the molecular information driving a patient’s cancer, so that optimum therapy can be selected for treatment,” said Biocept’s President and CEO Michael Nall. 4, 2020 /PRNewswire/ -- Biocept, Inc. com uses a Commercial suffix and it's server(s) are located in N/A with the IP number 104. BIOCEPT INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. December 11th, 2019 "Amedisys to Purchase Asana Hospice" “Since our founding, Asana Hospice has focused on family and patient-centered care and empowering each and every team member to take part in fulfilling this mission,” David Glick, president and CEO of Asana Hospice, said. Benzinga is covering every angle of how the coronavirus affects the financial world. Biocept partners with California physician association to provide cancer testing Monday, 10 February 2020 Biocept Inc (NASDAQ:BIOC), a provider of liquid biopsy tests, has struck up an agreement with an undisclosed independent physician association in California to provide liquid biopsy testing services to its physicians and patients. Take Care of Yourself Before You Take Care of Your Customer One of the most important questions people ask when they are focused on improving their quantity and quality of business is: ?What is my competitive advantage?. Jody Cain - LHA, IR. (the "Company") sets high standards for the Company's employees, officers and directors. This week Biocept Inc. , according to the company’s website (see here: www. & CEO Timothy Kennedy, SVP, Operations & CFO Lyle Arnold, PhD, SVP, R&D & CSO Michael Terry, SVP, Corp. Forecasting drug sales is a tricky business; just ask any biopharma CEO who has overpromised and underdelivered. BIOCEPT INC: BIOC: Nall Michael W. What's more, Nall says the developer of liquid biopsy tests has released a new Target Selector molecular assay research-use-only kit for clients to use in their own laboratories. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces the availability of 10,000 nasopharyngeal specimen collection kits for RT-PCR testing for SAR-CoV-2 (COVID-19) for physician ordering. Find the latest Biocept, Inc. org, Humor Train,. 's ISS Governance QualityScore as of N/A is N/A. Seite 34 der Diskussion 'Biocept, der nächste Highflyer?' vom 06. Box 801, in. Of this total $426,270 was received as a salary, $0 was received as a bonus, $0 was received in stock options, $0 was awarded as stock and $13,450 came from other types of compensation. com - May 13 at 9:08 PM: Biocept's Target Selector EGFR assay kit cleared in Europe; shares up 12% premarket seekingalpha. (NASDAQ:BIOC) in 2013. Michael Nall - President & CEO. Foletta (“ Executive ”), and shall be effective as of August 18, 2015 (the “ Effective Date ”). Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information. 8 million, more than double the prior year’s quarterly revenues,” said Michael Nall, President and CEO of Biocept. Biocept Inc Share Price and News. Forecasting drug sales is a tricky business; just ask any biopharma CEO who has overpromised and underdelivered. 333-234459 Dear Mr. CA, an investment chat community for Canada's small cap markets. a replay of the webcast will be. 45% gain Tuesday after announcing a lucrative contract. Real-time discussion about Biocept, Inc. Their average twelve-month price target is $1. Real-time trade and investing ideas on CannTrust CTST from the largest community of traders and investors. 13, 2020 at 8:41 p. Get detailed information on HC Surgical (1B1. is a molecular. Gratis precios de la bolsa en tiempo real, y los foros más activos del mercado accionario. "MCCP's network includes. Biocept, Inc. SAN DIEGO, June 22, 2020 /PRNewswire/ -- Biocept, Inc. Biocept, Inc. Biocept's services are available to medical and surgical oncologists, pathologists, hospitals, cancer centers, universities, and pharmaceutical and clinical researchers. is a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the. They also gave news headlines about the medical research company a news buzz of 0. SAN DIEGO, May 20, 2020 Biocept (BIOC), Inc. SAN DIEGO, May 20, 2020 /PRNewswire/ -- Biocept, Inc. , an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. Over the last four quarters, Biocept's revenue has grown by 21. (BIOC) CEO Michael Nall on Q4 2019 Results - Earnings Call Transcript 8:15PM ET 3/25/2020 Seeking Alpha Biocept (BIOC) Presents At BIO CEO & Investor Conference 2020 - Slideshow. Biocept, an emerging biotechnology leader in cell separation technology, is developing a new, powerful class of diagnostic assays for personalized medicine in early detection, diagnosis and monitoring of cancer. Ivor Royston biography. 8M; in Q3 2019, it was $1. Coronavirus Testing Expands In San Diego County pleased to support our clients and public health efforts by expanding our offerings to include COVID-19 testing," said Biocept CEO Mike Nall. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, reports financial results for the three and 12 months ended December 31, 2019, and provides an update on its business progress. They set a buy rating for […]. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces CE (Conformité Européene) IVD Marks and availability of its CEE-Sure® Blood Collection Tube and CEE-Sure® Sample Collection. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information. Biocept, Inc. Nall, Biocept President and CEO, will participate on the panel "COVID-19 Testing & Susceptibility - Clearing the Air". This LABORATORY SERVICES AGREEMENT (hereinafter referred to as the “Agreement” is made by and between Biocept, Inc. "We are pleased to welcome Dr. (NASDAQ:BIOC) Q1 2020 Results Conference Call May 13, 2020 4:30 PM ET Company Participants. Biocept's key executives include David F. Research Scientist II at Biocept, Inc. Here's the scoop: Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!. Find 4 questions and answers about working at BIOCEPT. 150 San Diego, CA 92121 USA. Biocept Inc (NASDAQ:BIOC) CEO Mike Nall tells Proactive that a peer-review journal named PLOS ONE has published validation results showing a higher sensitivity of the San Diego-based liquid biopsy provider's Target Selector, including its Switch-Blocker technology, which tests for rare cancers in plasma circulating tumor DNA. (NASDAQ:BIOC) Q4 2019 Results Earnings Conference Call March 25, 2020 4:30 PM ET Company Participants. Biocept was founded in 1997 and is headquartered in San Diego, California. Biocept to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020. SAN DIEGO, June 5, 2020 /PRNewswire/ -- Biocept, Inc. Benzinga is covering every angle of how the coronavirus affects the financial world. 91: 500 (Direct) View: 2019-04-30 Option Award: 2019-06-19 4:23 pm: N/A 2029-06-16: BIOCEPT INC: BIOC: HALE DAVID F Director: 500: $1. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. Biocept's President and CEO. 24 in early trading today on top of a 77. Biocept, Inc. Nall , Chief Executive Officer, received $1. Average pay of disclosed executives at Biocept Michael W. 09, FLORIDA STATUTES NOTICE IS HEREBY GIVEN that the undersigned, desiring to engage in business under the fictitious name of NO LIMIT RV SERVICES located at P. Biocept Inc (NASDAQ:BIOC) CEO Mike Nall tells Proactive that a peer-review journal named PLOS ONE has published validation results showing a higher sensitivity of the San Diego-based liquid biopsy provider's Target Selector, including its Switch-Blocker technology, which tests for rare cancers in plasma circulating tumor DNA. Biocept (BIOC) Releases CEO Letter to Stockholders Article Related Press Releases ( 1 ) Stock Quotes (1) Comments (0) FREE Breaking News Alerts from StreetInsider. Description: Biocept, Inc. stock is -63. “Our agreement with OHSU is a major milestone for Biocept, as we increase our commercial footprint by partnering with one of the most prestigious cancer centers in the nation,” added Michael W. For more information about Biocept, Inc. SAN DIEGO, Feb. Biocept Announces CE-IVD Mark And Availability Of Its Target Selector™ EGFR Molecular Assay Kit In Europe. Uncover why BIOCEPT is the best company for you. They also gave news headlines about the medical research company a news buzz of 0. COMMITMENT TO ACCURACY The Highlands News-Sun promptly corrects errors of fact appearing in its news stories. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. "This agreement effectively expands our managed care network of covered lives at a time when the healthcare community increasingly recognizes the importance of our liquid biopsy tests in helping physicians to determine the optimal treatment for their patients with cancer," said Michael Nall, Biocept's President and CEO. 4, 2020 /PRNewswire/ -- Biocept, Inc. Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year. SAN DIEGO, June 22, 2020 /PRNewswire/ -- Biocept, Inc. Salary ranges can vary widely depending on many important factors, including education , certifications, additional skills, the number of years you have spent in your profession. 44 percent to $1. 54,564 Watchers. Biocept (BIOC) Releases CEO Letter to Stockholders Article Related Press Releases ( 1 ) Stock Quotes (1) Comments (0) FREE Breaking News Alerts from StreetInsider. Nall will present a corporate overview at the 22 nd Annual BIO CEO & Investor Conference on Monday, February 10,. Biocept Inc is an early commercial-stage molecular oncology diagnostics company. Financial information: Would not disclose. 2 Wall Street analysts have issued ratings and price targets for Biocept in the last 12 months. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer,. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that Michael W. Nall will present a corporate overview at the 22 nd Annual BIO CEO & Investor Conference on Monday. 11, 2020 12:11 PM ET The following slide deck was published by Biocept, Inc. Get Biocept Inc (BIOC:NASDAQ) real-time stock quotes, news and financial information from CNBC. (NASDAQ:BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W. 3% to 58 cents at the time of publication Monday. Investors: Privately funded by the Reiss family and other undisclosed investors. (Nasdaq: BIOC) Shares of tiny Biocept Inc. CEO: 675,000: $0. (BIOC) , a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W. Implicit in this philosophy is the importance of sound corporate governance. BIOCEPT INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents. ) "MCCP has a reputation for paying out-of-network claims correctly, in full and on time; and we are delighted to be working with them," said Dede Goehler, Biocept's Senior Director of Managed Care Strategies. Biocept announced yesterday that Michael Nail, President and CEO of the company, will be giving a presentation at the LD Micro Invitational Conference on June 1, at 1:00PM Pacific time. Michael Nall, president and CEO of Biocept, said in a statement that gaining coverage by individual health plans like BCBS IL is a key aspect of the company's reimbursement strategy. Biocept Announces CE-IVD Mark and Availability of its Target Selector™ EGFR Molecular Assay Kit in Europe Target Selector™ assay kits enable assay developers to leverage Biocept's patented. Take Care of Yourself Before You Take Care of Your Customer One of the most important questions people ask when they are focused on improving their quantity and quality of business is: ?What is my competitive advantage?. 4, 2020 /PRNewswire/ -- Biocept, Inc. ET on Seeking Alpha Biocept up 12% premarket on assay nod in Europe. Biocept Inc (NASDAQ:BIOC) has agreed to a managed care provider agreement with Medical Cost Containment Professionals LLC (MCCP) to process out-of-network insurance claims for its Target Selector liquid biopsy testing. In this SNNLive Video Interview, our host spoke with Mike Nall, CEO of Biocept, Inc. , an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. Nall, also known as Mike, has been the Chief Executive Officer and President at Biocept, Inc. COVID-19 Test Successfully Used to Identify Coronavirus in Cancer Tissue News Feed [ May 26, 2020 ] Citius Announces Expanded Access Program for Investigational Phase 3 Mino-Lok® News Feed [ May 18, 2020 ] Citius Announces Closing of $7. com reaches roughly 2,646 users per day and delivers about 79,389 users each month. "I am very thankful to our laboratory team for stepping up and quickly validating COVID-19 testing, in addition to the vital work we do each day for patients diagnosed with cancer," Biocept CEO Mike Nall said in a statement. (NASDAQ:BIOC) since 2013. Address: 5810 Nancy Ridge Drive, Suite 150, San Diego, CA, USA, 92121: Telephone: +1 858 320-8200: Website: https://www. Hale and 8 others. Biocept, Inc. Biocept (NASDAQ: BIOC), a leading molecular oncology diagnostics company, reported a net loss for the second quarter. Biocept CEO Mike Nall said that while the company continued to focus primarily on providing "actionable results" for patients diagnosed with cancer, the company was pleased to support its clients and public health efforts by expanding its offerings "to include COVID-19 testing. 46 with a market cap of $40. (NASDAQ: BIOC), a leading provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, reports financial results for the three months ended March 31, 2020 and provides an update on its business progress. Berkshire (aktiencheck. Biocept, Inc. Financial information: Would not disclose. Maxim Group began coverage on shares of Biocept (NASDAQ:BIOC) in a report issued on Friday morning, TipRanks reports. "We are pleased to welcome Dr. Nall, Biocept (BIOC) President and CEO, will participate on the panel "COVID-19 Testing & Susceptibility - Clearing the Air. Thermo Fisher is set to collaborate with Biocept on the commercialization of liquid biopsies. In this SNNLive Video Interview, our host spoke with Mike Nall, CEO of Biocept, Inc. Nall made $439,720 in total compensation. People are so nice, and they really are like a family. About Biocept Biocept, Inc. Michael Nall - President and CEO. SAN DIEGO, June 5, 2020 /PRNewswire/ -- Biocept, Inc. 0 million and is part of the health care sector and health services industry. Cafepharma is a site for the pharmaceutical/medical industry. com reaches roughly 2,646 users per day and delivers about 79,389 users each month. 23M and analyst research firms have a positive stance on its shares. Nall will present a corporate overview at the 22 nd Annual BIO CEO & Investor Conference on Monday, February 10,. 8200 Fax: 858. The comapny announced that Michael W. (This number is for the twelve months until December 2018). Here's the scoop: Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!. Biocept President and CEO,. Biocept, Inc. SAN DIEGO, May 20, 2020 /PRNewswire/ -- Biocept, Inc. 2 on InfoTrie's scale. Industry, sector and description for Biocept. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces that it is relocating its corporate offices and CLIA-certified, CAP-accredited high complexity laboratory to a new location in San Diego. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. SAN DIEGO, June 5, 2020 /PRNewswire/ -- Biocept, Inc. Mike Nall has been the CEO of Biocept, Inc. (NASDAQ:BIOC) Q2 2019 Earnings Conference Call August 12, 2019 4:30 PM ET Company Participants. Biocept Insider Buying This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc. Nall, Biocept President and CEO, will participate on the panel "COVID-19 Testing & Susceptibility - Clearing the Air". Tim Kennedy – SVP, Operations & CFO. SAN DIEGO, Feb. 8M; in Q3 2019, it was $1. a replay of the webcast will be. is a leader in the development of more affordable and clinically actionable precision medicine strategies for the individual cancer patient. Related Links: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs. Description: Biocept, Inc. Biocept (NASDAQ: BIOC), a leading molecular oncology diagnostics company, reported a net loss for the second quarter. Hale was appointed Executive Chairman of Biocept in March 2011. Athersys was moving up 8. Jody Cain - LHA, IR. This LABORATORY SERVICES AGREEMENT (hereinafter referred to as the “Agreement” is made by and between Biocept, Inc. (NASDAQ:BIOC), on the other hand, is trading around $0. Biocept Logo (PRNewsFoto/Biocept, Inc. Report this profile; Activity. , a Chairman at Recros Medica, Inc. stocks as a “buy” while as. On Wednesday, Shares of UnitedHealth Group Inc (NYSE:UNH), gained 0. | 3,645 volgers op LinkedIn | When treating cancer, it's no longer an either/or world. Edwin Hendrick, Chief Commercial Officer Contact Info; Biocept Inc. Insider trades for Biocept Inc (BIOC). a replay of the webcast will be. 54,564 Watchers. 56, while of the analysts out of 0 who provided ratings for Biocept, Inc. Biocept Inc (NASDAQ: BIOC) is flying in the market this morning, and for good reason. Bigelow was the editor of. Biocept CEO Mike Nall said that while the company continued to focus primarily on providing "actionable results" for patients diagnosed with cancer, the company was pleased to support its clients and public health efforts by expanding its offerings "to include COVID-19 testing. Join to Connect. Sealing the deal for the Maxim analyst, is the company's. COMMITMENT TO ACCURACY The Highlands News-Sun promptly corrects errors of fact appearing in its news stories. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. See Michael W Nall's compensation, career history, education, & memberships. Jody Cain - LHA, IR. Historical Volatility. Benzinga is covering every angle of how the coronavirus affects the financial world. "MCCP's network includes. Hale is a Chairman at Adigica Health, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces the availability of 10,000 nasopharyngeal specimen collection kits for RT-PCR testing. CEO: Position is vacant. It's all about the AND. (BIOC) Stock Analysis & News | Seeking Alpha. Our team keeps improving our services, with every day, our professional staff is putting more efforts to bring level of our product’s quality even higher; we grow, learn and develop with every new customer. (NASDAQ:BIOC), a leading commercial. He is the Chairman & CEO of Hale BioPharma Ventures LLC, a private company focused on the formation and development of biotechnology, specialty pharma, diagnostic and medical device companies. 10, beats on revenue. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. BIOC 05/06/2020 22:41:02 1-888-992-3836 Free Membership Login Monitor. Thursday, October 01, 2015 $BIOC Biocept CEO Discusses Liquid Biopsy Diagnostic Test - StockNewsNow. Biocept To Accept COVID-19 Testing Requests. 91: 500 (Direct) View: 2019-04-30 Option Award: 2019-06-19 4:23 pm: N/A 2029-06-16: BIOCEPT INC: BIOC: HALE DAVID F Director: 500: $1. What's more, Nall says, is the California-based company is expanding its coronavirus molecular diagnostic test to its current client base, with a current capacity of 100 tests per day, with the. (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces that it is relocating its corporate offices and CLIA-certified, CAP-accredited high complexity laboratory to a new location in San Diego. Wilson is also a member of the board of directors of BioMed Realty Trust, Inc. The firm issued a buy rating and a $1. Find the latest Biocept, Inc. SAN DIEGO, May 20, 2020 Biocept (BIOC), Inc. Jody Cain - LHA IR. Dunn has served as Biocept's Vice President of Commercial Operations since October 2018. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. (the "Company") sets high standards for the Company's employees, officers and directors. The range between the high target price and low target price is between 1 and 1 calculating the mean target price we have 1. "I am very thankful to our laboratory team for stepping up and quickly validating COVID-19 testing, in addition to the vital work we do each day for patients diagnosed with cancer," Biocept CEO Mike Nall said in a statement. (NASDAQ: BIOC) via Skype. At the time of writing our data says that Biocept, Inc. Headquarters: San Diego, near the Sorrento Mesa area. We are investigating the potential for our lead product candidate, TAVO, through the intratumoral administration of IL-12, to stimulate systemic immune response and to become an innovative and potentially transformative therapy option for the treatment of cancer. Biocept to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020. The stock is trading on gains of over 10% after announcing that it may now commercialize its Target Selector kit products in the European Union. , LLC, a business management and strategic planning consulting firm, since 2003. Tim Kennedy - SVP, Operations & CFO. 4 million, representing a 41% increase over the prior-year period driven by a 27% increase in revenue per commercial accession," said Michael Nall, President and CEO of Biocept. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W.